These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 31973227

  • 1. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies.
    Chowdhury S, Sripathy S, Webster A, Park A, Lao U, Hsu JH, Loe T, Bedalov A, Simon JA.
    Molecules; 2020 Jan 21; 25(3):. PubMed ID: 31973227
    [Abstract] [Full Text] [Related]

  • 2. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
    Khalil NA, Ahmed EM, Zaher AF, El-Zoghbi MS, Sobh EA.
    Eur J Med Chem; 2020 Feb 01; 187():111926. PubMed ID: 31812033
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L, Ma X, Yuan C, He Y, Li L, Fang S, Xia W, He T, Qian S, Xu Z, Li G, Wang Z.
    Eur J Med Chem; 2017 Jul 07; 134():230-241. PubMed ID: 28415012
    [Abstract] [Full Text] [Related]

  • 4. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL, Wang HL, Zhong L, Yuan C, Liu SY, Yu ZJ, Liu S, Yan YH, Wu C, Wang Y, Wang Z, Yu Y, Chen Q, Li GB.
    Eur J Med Chem; 2018 Jul 15; 155():806-823. PubMed ID: 29957526
    [Abstract] [Full Text] [Related]

  • 5. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
    Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW.
    Mol Cancer Ther; 2010 Apr 15; 9(4):844-55. PubMed ID: 20371709
    [Abstract] [Full Text] [Related]

  • 6. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors.
    Mahajan SS, Scian M, Sripathy S, Posakony J, Lao U, Loe TK, Leko V, Thalhofer A, Schuler AD, Bedalov A, Simon JA.
    J Med Chem; 2014 Apr 24; 57(8):3283-94. PubMed ID: 24697269
    [Abstract] [Full Text] [Related]

  • 7. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
    Huang S, Song C, Wang X, Zhang G, Wang Y, Jiang X, Sun Q, Huang L, Xiang R, Hu Y, Li L, Yang S.
    J Chem Inf Model; 2017 Apr 24; 57(4):669-679. PubMed ID: 28301150
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
    Sakai T, Matsumoto Y, Ishikawa M, Sugita K, Hashimoto Y, Wakai N, Kitao A, Morishita E, Toyoshima C, Hayashi T, Akiyama T.
    Bioorg Med Chem; 2015 Jan 15; 23(2):328-39. PubMed ID: 25515955
    [Abstract] [Full Text] [Related]

  • 9. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile.
    Rotili D, Carafa V, Tarantino D, Botta G, Nebbioso A, Altucci L, Mai A.
    Bioorg Med Chem; 2011 Jun 15; 19(12):3659-68. PubMed ID: 21306905
    [Abstract] [Full Text] [Related]

  • 10. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
    Hoffmann G, Breitenbücher F, Schuler M, Ehrenhofer-Murray AE.
    J Biol Chem; 2014 Feb 21; 289(8):5208-16. PubMed ID: 24379401
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
    Hong JY, Fernandez I, Anmangandla A, Lu X, Bai JJ, Lin H.
    ACS Chem Biol; 2021 Jul 16; 16(7):1266-1275. PubMed ID: 34139124
    [Abstract] [Full Text] [Related]

  • 12. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
    Cui H, Kamal Z, Ai T, Xu Y, More SS, Wilson DJ, Chen L.
    J Med Chem; 2014 Oct 23; 57(20):8340-57. PubMed ID: 25275824
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.
    Yoon YK, Ali MA, Wei AC, Choon TS, Osman H, Parang K, Shirazi AN.
    Bioorg Med Chem; 2014 Jan 15; 22(2):703-10. PubMed ID: 24387981
    [Abstract] [Full Text] [Related]

  • 14. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.
    Seifert T, Malo M, Kokkola T, Engen K, Fridén-Saxin M, Wallén EA, Lahtela-Kakkonen M, Jarho EM, Luthman K.
    J Med Chem; 2014 Dec 11; 57(23):9870-88. PubMed ID: 25383691
    [Abstract] [Full Text] [Related]

  • 15. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
    Yagci S, Gozelle M, Kaya SG, Ozkan Y, Aksel AB, Bakar-Ates F, Dundar Y, Eren G.
    Bioorg Med Chem; 2021 Jan 15; 30():115961. PubMed ID: 33360574
    [Abstract] [Full Text] [Related]

  • 16. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
    Farooqi AS, Hong JY, Cao J, Lu X, Price IR, Zhao Q, Kosciuk T, Yang M, Bai JJ, Lin H.
    J Med Chem; 2019 Apr 25; 62(8):4131-4141. PubMed ID: 30986062
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
    Khanfar MA, Quinti L, Wang H, Choi SH, Kazantsev AG, Silverman RB.
    Eur J Med Chem; 2014 Apr 09; 76():414-26. PubMed ID: 24602787
    [Abstract] [Full Text] [Related]

  • 18. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
    Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B.
    Biochem Biophys Res Commun; 2009 Sep 04; 386(4):729-33. PubMed ID: 19559674
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
    Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N.
    J Med Chem; 2012 Jun 28; 55(12):5760-73. PubMed ID: 22642300
    [Abstract] [Full Text] [Related]

  • 20. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
    Disch JS, Evindar G, Chiu CH, Blum CA, Dai H, Jin L, Schuman E, Lind KE, Belyanskaya SL, Deng J, Coppo F, Aquilani L, Graybill TL, Cuozzo JW, Lavu S, Mao C, Vlasuk GP, Perni RB.
    J Med Chem; 2013 May 09; 56(9):3666-79. PubMed ID: 23570514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.